Daclizumab


Daclizumab
Daclizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD25
Clinical data
Trade names Zenapax
AHFS/Drugs.com monograph
Pregnancy cat. C
Legal status European marketing authorisation withdrawn
Routes intravenous
Pharmacokinetic data
Half-life 20 days
Identifiers
CAS number 152923-56-3 YesY
ATC code L04AC01
DrugBank BTD00007
UNII CUJ2MVI71Y YesY
ChEMBL CHEMBL1201605 N
Chemical data
Formula C6332H9808N1678O1989S42 
Mol. mass 142612.1 g/mol
 N(what is this?)  (verify)

Daclizumab (trade name Zenapax) is a therapeutic humanized monoclonal antibody to the alpha subunit of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Daclizumab is currently in phase II clinical trials in the U.S.

In April 2008, Hoffmann-La Roche, the pharmeceutical company that markets Daclizumab (under the name "Zenapax") in Europe, submitted an application to have its marketing authorisation withdrawn in the EU for commercial reasons. The drug faced diminishing market demand, according to the company. There were no safety concerns with its use. As of January 2009, its marketing authorisation has been withdrawn and the product discontinued completely.[1][2]

It is given in multiple doses, the first 1 hour before the transplant operation and 5 further doses given at two week intervals after the transplant. These saturate the receptors and prevent T cell activation and thus prevent formation of antibodies against the transplant.

Like the similar drug basiliximab, daclizumab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections.

Daclizumab usage may also be indicated in place of a calcineurin-inhibitor (ciclosporin or tacrolimus) during the early phase after kidney transplantation, when the kidney is recovering and vulnerable to calcineurin-inhibitor toxicity. This has been shown to be beneficial in non-heart beating donor kidney transplantation.

In the United Kingdom, the National Institute for Health and Clinical Excellence has recommended its use be considered for all kidney transplant recipients.[citation needed]

In 2006 it began a Phase II clinical trial that finished in 2007 as a possible Multiple Sclerosis treatment. Participants were nine patients with multiple sclerosis not controlled with interferon. Daclizumab was effective in reducing lesions and improving clinical scores.[3]

Daclizumab has also been used to slow the progression of autoimmune diseases, particularly that of birdshot chorioretinopathy.[4]

References

  1. ^ British National Formulary, Edition 57
  2. ^ EMEA: Withdrawal of the marketing authorisation in the European Union
  3. ^ Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007). "Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results". Neurology 69 (8): 785–789. doi:10.1212/01.wnl.0000267662.41734.1f. PMID 17709711. 
  4. ^ Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS (2008). "Daclizumab for treatment of birdshot chorioretinopathy". Arch Ophthalmol. 126 (2): 186–191. doi:10.1001/archophthalmol.2007.49. PMID 18268208. 

Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Daclizumab — Masse/Länge Primärstruktur 142,6 kDa …   Deutsch Wikipedia

  • daclizumab — es un anticuerpo monoclonal inmunosupresor humanizado IgG1 producido mediante la tecnología del ADN recombinante, que se une específicamente a la subunidad a del receptor de interleukina 2 expresado en la superficie de los linfocitos activados.… …   Diccionario médico

  • daclizumab — noun A humanized monoclonal antibody used to prevent rejection in organ transplantation, especially in kidney transplants …   Wiktionary

  • daclizumab — da·cliz·u·mab (də klizґu mab) an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously …   Medical dictionary

  • daclizumab — A monoclonal antibody that is being studied in the treatment of adult T cell leukemia and in the treatment of cytopenia (low blood cell count). Also called dacliximab …   English dictionary of cancer terms

  • Monoclonal antibodies — A general representation of the methods used to produce monoclonal antibodies. Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are the same because they are made by identical immune cells that are all clones of a unique… …   Wikipedia

  • Birdshot chorioretinopathy — Infobox Disease Name = PAGENAME Caption = DiseasesDB = 32404 ICD10 = ICD10|H|30|9|h|30 ICD9 = ICD9|363.20 ICDO = OMIM = 605808 MedlinePlus = eMedicineSubj = eMedicineTopic = MeshID = Birdshot chorioretinopathy, also called birdshot… …   Wikipedia

  • Omalizumab — ? Monoclonal antibody Type Whole antibody Source Humanized (from mouse) Target IgE Fc region …   Wikipedia

  • Natalizumab — ? Monoclonal antibody Type Whole antibody Source Humanized (from mouse) Target alpha 4 integrin Clinical data Trade names Tysabri AHFS/ …   Wikipedia

  • Monoclonal antibody therapy — Each antibody binds only one specific antigen. Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically bind to target cells or proteins. This may then stimulate the patient s immune system to attack those cells.… …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.